Clinical Trials Logo

Clinical Trial Summary

Hypomagnesemia (hMg) is a common side effect of important anti-cancer therapies such as epidermal growth factor receptor inhibitors (EGFRIs) and platinum-containing anti-cancer drugs. EGFRIs, including cetuximab (cmab) and panitumumab (pmab), have been estimated to cause hMg in over 18% and 27% of patients respectively1, while 90% of patients receiving cisplatin will develop hMg if left untreated. The development of severe hMg may result in increased symptoms such as fatigue, neuromuscular changes, mental status changes and cardiac arrhythmias which could result in treatment delays and may compromise treatment efficacy. Despite the common occurrence of this toxicity, little is known regarding the optimal magnesium management strategy. As physicians do not know what the "best" treatment for patients is, genuine uncertainty ("clinical equipoise") exists. Physicians will choose between different "standards" of magnesium replacement in their personal practice, using idiosyncratic decision making processes, without the physician or the patient knowing the optimal option. This is not good for patients, physicians and society as a whole. Determining the optimal treatment remains an important medical issue for patients, physicians and society. This study will use a novel method to allow comparisons of established standard of care prophylactic treatment using the "integrated consent model" as part of a pragmatic clinical trial7. By integrating medical and clinical practices, physicians will be able to inform their patients about the randomized control trial, akin to a typical conversation between the physician and patient, without written informed consent. This clinical interaction would then be documented, as ordinarily done in practice. Medical and clinical practice will be intertwined with the patients' welfare at the forefront of our best interests.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02690012
Study type Interventional
Source Ottawa Hospital Research Institute
Contact
Status Completed
Phase N/A
Start date July 2016
Completion date March 2019

See also
  Status Clinical Trial Phase
Completed NCT01700998 - Magnesium Replacement Therapy to Prevent Acute Renal Failure in Critically Ill Patients N/A
Recruiting NCT03088852 - Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards Phase 4
Active, not recruiting NCT03976440 - Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
Completed NCT00603499 - Magnesium and Metabolic Syndrome Phase 4
Completed NCT04426994 - Hypomagnesemia Associated With Proton-Pump Inhibitor Use
Completed NCT00994006 - The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects Phase 4
Recruiting NCT00282620 - Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life. Phase 4
Completed NCT04351451 - Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy
Terminated NCT03812380 - Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate Phase 3
Recruiting NCT04382157 - Magnesium Replacement and Hyperglycemia After Kidney Transplantation Phase 1/Phase 2
Completed NCT02216877 - Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease Phase 1/Phase 2
Recruiting NCT05998863 - EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy Phase 3
Not yet recruiting NCT06353750 - Intracellular Magnesium and Heart Failure